Opioid Use After Hip Fracture and Subsequent Fracture Outcomes: A Self‐Controlled Case Series Design
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Meghan A Cupp und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Hip Fractures, Analgesics, Opioid, Pain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
Purpose
Hip fractures in older adults cause severe pain that often necessitates opioid use. However, opioids may trigger falls that result in subsequent fractures. Studies examining the effects of opioids on subsequent fractures are often limited by unmeasured confounding between opioid‐treated and untreated persons. To overcome this limitation, we used a self‐controlled case series (SCCS) design to investigate subsequent fracture risk during periods of opioid use after hip fracture.
Methods
The retrospective cohort included Medicare beneficiaries aged > 65 years who had a subsequent hip fracture within one year after an incident hip fracture (2012–2018). We estimated the risk of subsequent hip fracture in three exposure intervals according to the duration of opioid exposure: (1) The first 0–14 days of opioid exposure, (2) days 15–42 of exposure, and (3) opioid use beyond 42 days. We employed several approaches to modify the SCCS design to be more robust to assumptions, including adjustment for event‐dependent exposures.
Results
The rate of subsequent fracture was greatest during opioid use across a variety of approaches. The effect within the first 14 days after initiating opioids was robust to SCCS design choices, ranging from IRR 1.12 (95%CLs 0.98, 1.28) to IRR 1.77 (95%CLs 1.52, 2.07). The effect of extended opioid use (> 42 days) ranged from IRR 2.49 (95%CLs 1.95, 3.18) to IRR 4.08 (95%CLs 3.06, 5.46).
Conclusions
Analyses indicate a consistent increased risk of subsequent fracture associated with opioid use and demonstrate the importance that SCCS assumptions must be carefully investigated for real‐world applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island, USA.
- Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island, USA.
- Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA.
- Center of Innovation in Long-Term Services and Supports, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA.
- Department of Pharmacy, Rhode Island Hospital, Providence, Rhode Island, USA.
ORCID-Profile: Meghan A Cupp, Andrew R Zullo
Förderung
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Cupp, M. A., Hayes, K. N., Berry, S. D., Beaudoin, F. L., Riester, M. R., Joshi, R., & Zullo, A. R. (2025). Opioid Use After Hip Fracture and Subsequent Fracture Outcomes: A Self‐Controlled Case Series Design. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70118
Vancouver
Cupp MA, Hayes KN, Berry SD, Beaudoin FL, Riester MR, Joshi R, et al. Opioid Use After Hip Fracture and Subsequent Fracture Outcomes: A Self‐Controlled Case Series Design. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70118
BibTeX
@article{Cupp2025,
author = {Cupp, Meghan A and Hayes, Kaleen N and Berry, Sarah D and Beaudoin, Francesca L and Riester, Melissa R and Joshi, Richa and Zullo, Andrew R},
title = {Opioid Use After Hip Fracture and Subsequent Fracture Outcomes: A Self‐Controlled Case Series Design},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70118}
}
EUVIMED